Cargando…
Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
BACKGROUND: The recently developed reagent, eribulin mesylate (eribulin), is a microtubule dynamics inhibitor with a mechanism of action that differs from those of taxanes and vinca alkaloids. This drug is considered to be a promising chemotherapeutic agent for the treatment of locally advanced or m...
Autores principales: | Kashiwagi, Shinichiro, Fukushima, Wakaba, Asano, Yuka, Goto, Wataru, Takada, Koji, Noda, Satoru, Takashima, Tsutomu, Onoda, Naoyoshi, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580315/ https://www.ncbi.nlm.nih.gov/pubmed/28859615 http://dx.doi.org/10.1186/s12885-017-3598-5 |
Ejemplares similares
-
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017) -
Multiple metastatic malignant phyllodes tumor of the breast with tonsillar metastasis: a case report
por: Sera, Tomohiro, et al.
Publicado: (2017) -
Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2017) -
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
por: Kashiwagi, Shinichiro, et al.
Publicado: (2018) -
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
por: Asano, Yuka, et al.
Publicado: (2017)